Investor Presentaiton slide image

Investor Presentaiton

Strong revenue growth and major Therapy Selection tailwinds in 1H 2023 $266M $205M 30% Total Revenue YoY Growth Recent Highlights INVESTOR 20 DAY 23 Guardant360 CDx breast FDA approval Guardant360 expanded reimbursement GUARDANTâ„¢ 1H 2022 1H 2023 Guardant360 Japan reimbursement Response Medicare coverage EMR integrations 144
View entire presentation